Views & Analysis Almirall gets in on the eczema action Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall wants a piece of the action.
Views & Analysis Patient Insights: Severe psoriasis & eczema Howard Chang has lived with severe psoriasis and atopic dermatitis for almost 40 years since childhood.
News FDA approves Sanofi/Regeneron's Dupixent in asthma The US regulator has approved Sanofi/Regeneron’s Dupixent (dupilumab) in a new asthma indication, a key step in the companies attempt to build a blockbuster franchise around the drug.
News Sanofi showcases eczema data ahead of EU decision Dupixent predicted to be blockbuster for Sanofi
News Roche sells rights to troubled asthma and eczema drug Dermira will focus on development in eczema.
News Sanofi/Regeneron eczema data paves way for year's biggest la... Companies look to take on Pfizer after series of setbacks.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
